The role and efficacy of Ado-trastuzumab emtansine

Ado-trastuzumab emtansine is a humanized monoclonal antibody targeting the HER2 receptor and has a microtubule inhibitor. It is approved for the treatment of metastatic HER2-positive breast cancer after treatment with trastuzumab and taxanes. While trastuzumab has been shown to be effective in the treatment of drug-resistant breast cancer, it has also shown efficacy in the adjuvant setting.

The active substances in Emtansine trastuzumabtrastuzumab and emtansine are composed of two interconnected active ingredients. Trastuzumab is a monoclonal antibody designed to recognize and attach to the HER2 protein, which is abundantly present on the surface of some cancer cells. By linking to HER2, trastuzumab activates cells of the immune system, which then kills cancer cells. Trastuzumab also prevents HER2 from stimulating the growth of cancer cells. DM1 is a toxic substance that kills cells when they try to divide and grow. Once trastuzumab enters the cancer cells, DM1 becomes active. It attaches to a protein in cells called tubulin. By attaching to tubulin in cancer cells, DM1 prevents the formation of this skeleton, thereby preventing the cancer cells from dividing and growing.

EnmetratrastuzumabThe monoclonal antigenic drug has been launched in China and has entered the scope of medical insurance. Only eligible patients can be reimbursed. SpecificationsThe price of 100mg per box may be around 20,000 yuan. This drug is a strictly controlled drug. Listed overseas Enmei Trastuzumab The single-unit generic drug has Turkish and European versions, with specifications The price of each box of 100 mg may be around 3,000-8,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the originator drugs sold domestically and abroad are basically the same, and there are currently no generic versions of Enmei Trastuzumab produced and launched.